NASDAQ · TCRX
TScan Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TCRX: Nov 11, 2026
TScan Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.28.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.08 | $-0.24 | 3 |
| Dec 2026 | $-0.15 | $-0.09 | $-0.21 | 3 |
| Mar 2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Jun 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Sep 4, 10:09 AM EDTWeekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) – This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring moves. Ionis, Milestone, Novavax advanced key programs, while United Imaging gaine
- RTTNews · Sep 2, 9:03 AM EDTTScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%(RTTNews) – TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company, announced Wednesday it is reorganizing strategically to prioritize its in vivo solid tumor program and advance two product candidates to IND-enabling studies.
- RTTNews · Aug 12, 12:43 PM EDTTScan Advances TSC-101; Phase 3 Topline Data Expected In 2028(RTTNews) – TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company developing TCR-engineered T cell (TCR-T) therapies for cancer, has reported its second-quarter 2026 financial results and provided business updates, highlighting the Phase 3 advancement of TSC-101
- Zacks · Aug 12, 8:10 AM EDTTScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue EstimatesTScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 9:50 AM EDTPrime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue EstimatesPrime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 31, 5:34 AM EDTTScan Treats First Patient In Phase 3 Trial Of TSC-101 For Heme Malignancies(RTTNews) – Tscan Therapeutics (TCRX), a clinical-stage biotechnology company developing T-cell receptor engineered T-cell therapies for cancer, announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2 trial.
- Zacks · May 6, 8:25 AM EDTTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesTScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 4, 8:15 AM ESTTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesTScan Therapeutics (TCRX) delivered earnings and revenue surprises of +34.31% and -37.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Feb 25, 12:15 PM ESTRecursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue EstimatesRecursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Feb 12, 7:40 AM ESTAgios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue EstimatesAgios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +6.25% and +94.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Feb 11, 7:25 AM ESTSutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks · Feb 6, 8:15 AM ESTRoivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue EstimatesMontes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +9.43% and -67.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for TScan Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.